Study 171 Shows Hypoglycemia is Reduced with Use of Afrezza® Relative to Insulin Aspart in Type 1 Diabetes

About this update from Mannkind Corporation

[{"type":"text","content":"Publication in DIABETICMedicine Now Available Online\nWESTLAKE VILLAGE, Calif., Dec. 20, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) announced today that Hypoglycemia is reduced with use of inhaled Technosphere® Insulin relative to insulin aspart in type 1 diabetes mellitus has been published online in DIABETICMedicine.\n This post-hoc analysis was designed to further evaluate the risk of hypoglycemia observed in adults with type 1 diabetes who were treated with inhaled Technosphere Insulin (Afrezza®) or subcutaneous insulin aspart. Specifically, the research controlled for the level of any HbA1c achieved on the incidence rates of hypoglycemia (low levels of sugar in the blood) in 375 adults with type 1 diabetes. The data demonstrated the following: Participants treated with Afrezza experienced statistically significantly lower rates of level 1 (blood glucose ≤ 3.9 mmol/L or 70 mg/dL) and level 2 (blood glucose ≤ 3.0 mmol/L or 54 mg/dL) hypoglycemic events. There was also a trend towards lower rates of level 3 hypoglycemia (requiring external assistance for recovery) than participants treated with insulin aspart.The lower rate of hypoglycemia with Afrezza was observed across the range of end-of-treatment A1c levels.Due to its unique pharmacokinetic/pharmacodynamic profile, Afrezza was associated with higher rates of hypoglycemia 30–60 minutes after meals but significantly lower rates 2–6 hours after meals. These data indicate that participants using Afrezza experienced clinically non-inferior glycemic control and lower hypoglycemia rates across a range of A1c levels compared with participants receiving insulin aspart. Hypoglycemia and fear of hypoglycemia are barriers to effective insulin therapy and may prevent people with diabetes from achieving glycemic targets. Potential risks associated with hypoglycemia include, but are not limited to, treatment costs, limiting the individual patient’s capacity to intensify diabetes control, individual patient rates of productivity, as well as many other debilitating effects. The published research can be found online at https://onlinelibrary.wiley.com/doi/abs/10.1111/dme.14202 About Afrezza® Available by prescription, Afrezza® (insulin human) Inhalation Powder is a rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus....

More updates from Mannkind Corporation